UCB Licenses Sepracor, Inc. U.S. Patents For Antihistamine Levocetirizine

UCB S.A. (EURONEXT: UCB) and Sepracor Inc. (Nasdaq: SEPR) today announced a licensing agreement relating to the antihistamine levocetirizine. Under this agreement, Sepracor has exclusively licensed to UCB all of Sepracor's patents and patent applications in the United States regarding levocetirizine and royalties will be payable to Sepracor on U.S. sales of levocetirizine products.

Back to news